Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Roflumilast in COPD: a Brazilian perspective

Authors Stirbulov R, Jardim JR

Received 7 April 2015

Accepted for publication 24 July 2015

Published 8 September 2015 Volume 2015:10(1) Pages 1853—1855

DOI https://doi.org/10.2147/COPD.S64455

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell


Roberto Stirbulov,1 José R Jardim2

1Department of Respiratory Diseases, Santa Casa School of Medical Sciences in São Paulo, 2Department of Respiratory Diseases, Escola Paulista de Medicina, Federal University of São Paulo, Hospital São Paulo, São Paulo, Brazil

We would like to discuss the use of roflumilast in Brazil and its perspectives, based on the data currently available. This medication is underused in Brazil, probably due to its high cost in the public health care system. Of the approximately 21,000 patients who have a condition which could be treated with roflumilast (personal communication, Takeda Pharmaceutical Company, 2014), only 14% are currently using it.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]